{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:03:51Z","timestamp":1791896631038,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s11940-006-0033-7","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T21:14:24Z","timestamp":1181078064000},"page":"441-450","source":"Crossref","is-referenced-by-count":15,"title":["Diagnosis and treatment of neurotransmitter disorders"],"prefix":"10.1007","volume":"8","author":[{"given":"Phillip L.","family":"Pearl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Hartka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Suppl 6","key":"33_CR1","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ana.10627","volume":"54","author":"K Hyland","year":"2003","unstructured":"Hyland K: The lumbar puncture for diagnosis of pediatric neurotransmitter diseases. Ann Neurol 2003, 54(Suppl 6):S13-S17. Overview of CSF neurotransmitter studies from the only laboratory currently offering clinical testing in the United States.","journal-title":"Ann Neurol"},{"key":"33_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/brain\/awf090","volume":"125","author":"AH Nemeth","year":"2002","unstructured":"Nemeth AH: The genetics of primary dystonias and related disorders. Brain 2002, 125:695\u2013721.","journal-title":"Brain"},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/brain\/123.6.1112","volume":"123","author":"J Tassin","year":"2000","unstructured":"Tassin J, Durr A, Bonnet AM, et al.: Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?\n                           Brain 2000, 123:1112\u20131121.","journal-title":"Brain"},{"issue":"Suppl 6","key":"33_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1002\/ana.10631","volume":"54","author":"KJ Swoboda","year":"2003","unstructured":"Swoboda KJ, Saul JP, McKenna CE, et al.: Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol 2003, 54(Suppl 6):S49-S55.","journal-title":"Ann Neurol"},{"key":"33_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0022-3476(05)80610-9","volume":"120","author":"S Kure","year":"1992","unstructured":"Kure S, Narisawa K, Tada K: Enzymatic diagnosis of nonketotic hyperglycinemia with lymphoblasts. J Pediatr 1992, 120:95\u201398.","journal-title":"J Pediatr"},{"key":"33_CR6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1570-9639(03)00045-1","volume":"1647","author":"P Baxter","year":"2003","unstructured":"Baxter P: Pyridoxine-dependent seizures: a clinical and biochemical conundrum. Biochim Biophys Acta 2003, 1647:36\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"33_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.55.2.309","volume":"55","author":"G Battaglioli","year":"2000","unstructured":"Battaglioli G, Rosen DR, Gospe SM Jr, et al.: Glutamate decarboxylase is not genetically linked to pyridoxinedependent seizures. Neurology 2000, 55:309\u2013311.","journal-title":"Neurology"},{"key":"33_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1086\/303087","volume":"67","author":"V Cormier-Daire","year":"2000","unstructured":"Cormier-Daire V, Dagoneau N, Nabbout R, et al.: A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31. Am J Hum Genet 2000, 67:991\u2013993.","journal-title":"Am J Hum Genet"},{"key":"33_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10048-005-0221-8","volume":"6","author":"CL Bennett","year":"2005","unstructured":"Bennett CL, Huynh HM, Chance PF, et al.: Genetic heterogeneity for autosomal recessive pyridoxine-dependent seizures. Neurogenetics 2005, 6:143\u2013149.","journal-title":"Neurogenetics"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/1531-8249(200007)48:1<121::AID-ANA20>3.0.CO;2-V","volume":"48","author":"B Plecko","year":"2000","unstructured":"Plecko B, Stockler-Ipsiroglu S, Paschke E, et al.: Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol 2000, 48:121\u2013125.","journal-title":"Ann Neurol"},{"key":"33_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm1366","volume":"12","author":"PB Mills","year":"2006","unstructured":"Mills PB, Struys E, Jakobs C, et al.: Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006, 12:307\u2013309.","journal-title":"Nat Med"},{"key":"33_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/hmg\/ddi120","volume":"14","author":"PB Mills","year":"2005","unstructured":"Mills PB, Surtees RA, Champion MP, et al.: Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5\u2032-phosphate oxidase. Hum Mol Genet 2005, 14:1077\u20131086.","journal-title":"Hum Mol Genet"},{"key":"33_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2005.09.012","volume":"38","author":"PL Pearl","year":"2005","unstructured":"Pearl PL, Capp PK, Novotny EJ, et al.: Inherited disorders of neurotransmitters in children and adults. Clin Biochem 2005, 38:1051\u20131058.","journal-title":"Clin Biochem"},{"key":"33_CR14","first-page":"203","volume-title":"Paediatric Movement Disorders","author":"P Pearl","year":"2005","unstructured":"Pearl P, Acosta MT, Wallis DD, et al.: Dyskinetic features of succinate semialdehyde dehydrogenase deficiency, a GABA degradative defect. In Paediatric Movement Disorders. Edited by Fernandez-Alvarez E, Arzimanoglou A, Tolosa E. Montrouge, France: John Libbey Eurotext Ltd.; 2005:203\u2013212."},{"key":"33_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/humu.10288","volume":"22","author":"S Akaboshi","year":"2003","unstructured":"Akaboshi S, Hogema BM, Novelletto A, et al.: Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 2003, 22:442\u2013450.","journal-title":"Hum Mutat"},{"key":"33_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2002-23590","volume":"33","author":"O Bandmann","year":"2002","unstructured":"Bandmann O, Wood NW: Dopa-responsive dystonia--the story so far. Neuropediatrics 2002, 33:1\u20135.","journal-title":"Neuropediatrics"},{"issue":"Suppl 6","key":"33_CR17","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1002\/ana.10630","volume":"54","author":"M Segawa","year":"2003","unstructured":"Segawa M, Nomura Y, Nishiyama N: Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003, 54(Suppl 6):S32-S45. This report is contained in a special monograph of the proceedings of a National Institutes of Health\/PNDA-sponsored meeting on the pediatric neurotransmitter disorders held May 2002 in Bethesda, MD.","journal-title":"Ann Neurol"},{"key":"33_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1353-8020(00)00084-5","volume":"8","author":"WJ Hwang","year":"2001","unstructured":"Hwang WJ, Calne DB, Tsui JK, et al.: The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord 2001, 8:1\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"33_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/jnnp.63.3.304","volume":"63","author":"PR Jarman","year":"1997","unstructured":"Jarman PR, Bandmann O, Marsden CD, et al.: GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry 1997, 63:304\u2013308.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"33_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0733-8619(02)00018-X","volume":"20","author":"KJ Swoboda","year":"2002","unstructured":"Swoboda KJ, Hyland K: Diagnosis and treatment of neurotransmitter-related disorders. Neurol Clin 2002, 20:1143\u20131161, viii.","journal-title":"Neurol Clin"},{"key":"33_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ana.20055","volume":"55","author":"YT Chang","year":"2004","unstructured":"Chang YT, Sharma R, Marsh JL, et al.: Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. Ann Neurol 2004, 55:435\u2013438.","journal-title":"Ann Neurol"},{"key":"33_CR22","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.62.7.1058","volume":"62","author":"R Pons","year":"2004","unstructured":"Pons R, Ford B, Chiriboga CA, et al.: Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 2004, 62:1058\u20131065.","journal-title":"Neurology"},{"key":"33_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/s-2002-34497","volume":"33","author":"A Fiumara","year":"2002","unstructured":"Fiumara A, Brautigam C, Hyland K, et al.: Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics 2002, 33:203\u2013208.","journal-title":"Neuropediatrics"},{"key":"33_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/mds.10095","volume":"17","author":"PJ Grattan-Smith","year":"2002","unstructured":"Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, et al.: Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002, 17:354\u2013359.","journal-title":"Mov Disord"},{"key":"33_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0022-3476(00)90027-1","volume":"136","author":"C Dionisi-Vici","year":"2000","unstructured":"Dionisi-Vici C, Hoffmann GF, Leuzzi V, et al.: Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr 2000, 136:560\u2013562.","journal-title":"J Pediatr"},{"key":"33_CR26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1212\/01.WNL.0000156800.23776.40","volume":"64","author":"A Dinopoulos","year":"2005","unstructured":"Dinopoulos A, Kure S, Chuck G, et al.: Glycine decarboxylase mutations: a distinctive phenotype of nonketotic hyperglycinemia in adults. Neurology 2005, 64:1255\u20131257.","journal-title":"Neurology"},{"key":"33_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/08830738040190010702","volume":"19","author":"YH Chien","year":"2004","unstructured":"Chien YH, Hsu CC, Huang A, et al.: Poor outcome for neonatal-type nonketotic hyperglycinemia treated with high-dose sodium benzoate and dextromethorphan. J Child Neurol 2004, 19:39\u201342.","journal-title":"J Child Neurol"},{"key":"33_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.20159","volume":"56","author":"SH Korman","year":"2004","unstructured":"Korman SH, Boneh A, Ichinohe A, et al.: Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation. Ann Neurol 2004, 56:139\u2013143.","journal-title":"Ann Neurol"},{"key":"33_CR29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/08830738060210011801","volume":"21","author":"H Tekgul","year":"2006","unstructured":"Tekgul H, Serdaroglu G, Karapinar B, et al.: Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia. J Child Neurol 2006, 21:82\u201384.","journal-title":"J Child Neurol"},{"key":"33_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1017\/S0012162201000767","volume":"43","author":"E Grillo","year":"2001","unstructured":"Grillo E, da Silva RJ, Barbato JH Jr: Pyridoxine-dependent seizures responding to extremely low-dose pyridoxine. Dev Med Child Neurol 2001, 43:413\u2013415.","journal-title":"Dev Med Child Neurol"},{"key":"33_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/adc.2004.052837","volume":"90","author":"P Baxter","year":"2005","unstructured":"Baxter P: Pyridoxine or pyridoxal phosphate for intractable seizures?\n                           Arch Dis Child 2005, 90:441\u2013442. Recommended editorial detailing the pyridoxine versus P5P debate from a recognized expert in pyridoxinedependent epilepsy.","journal-title":"Arch Dis Child"},{"key":"33_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/adc.2003.045963","volume":"90","author":"HS Wang","year":"2005","unstructured":"Wang HS, Kuo MF, Chou ML, et al.: Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child 2005, 90:512\u2013525.","journal-title":"Arch Dis Child"},{"key":"33_CR33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/01.WNL.0000059549.70717.80","volume":"60","author":"PL Pearl","year":"2003","unstructured":"Pearl PL, Gibson KM, Acosta MT, et al.: Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003, 60:1413\u20131417. Report of the clinical phenotype of the most common neurotransmitter disorder.","journal-title":"Neurology"},{"key":"33_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ana.10752","volume":"54","author":"K Ergezinger","year":"2003","unstructured":"Ergezinger K, Jeschke R, Frauendienst-Egger G, et al.: Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003, 54:686\u2013689.","journal-title":"Ann Neurol"},{"key":"33_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.20084","volume":"55","author":"PL Pearl","year":"2004","unstructured":"Pearl PL, Gropman A: Monitoring gamma-hydroxybutyric acid levels in succinate-semialdehyde dehydrogenase deficiency. Ann Neurol 2004, 55:599; author reply 599.","journal-title":"Ann Neurol"},{"issue":"Suppl 6","key":"33_CR36","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1002\/ana.10626","volume":"54","author":"A Gropman","year":"2003","unstructured":"Gropman A: Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003, 54(Suppl 6):S66-S72. Emphasis on treatment options in SSADH deficiency.","journal-title":"Ann Neurol"},{"key":"33_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ng727","volume":"29","author":"BM Hogema","year":"2001","unstructured":"Hogema BM, Gupta M, Senephansiri H, et al.: Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat Genet 2001, 29:212\u2013216.","journal-title":"Nat Genet"},{"issue":"Suppl 6","key":"33_CR38","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1002\/ana.10625","volume":"54","author":"M Gupta","year":"2003","unstructured":"Gupta M, Hogema BM, Grompe M, et al.: Murine succinate semialdehyde dehydrogenase deficiency. Ann Neurol 2003, 54(Suppl 6):S81-S90. Comprehensive report on murine SSADH, serving as a prototype of genetic degradative technology to develop animal models for further research.","journal-title":"Ann Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-006-0033-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0033-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:31:22Z","timestamp":1652614282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-006-0033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s11940-006-0033-7","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}